Close Menu
    Facebook X (Twitter) Instagram
    Monday, June 29
    Top Stories:
    • California’s New Law Puts a Muzzle on Loud Streaming Ads Starting July 1
    • China Worries Over Privacy Amid Rise of AI Smart Glasses
    • Capricor Faces New Challenge as FDA Schedules DMD Cardio Therapy Review
    Facebook X (Twitter) Instagram Pinterest Vimeo
    IO Tribune
    • Home
    • AI
    • Tech
      • Gadgets
      • Fashion Tech
    • Crypto
    • Smart Cities
      • IOT
    • Science
      • Space
      • Quantum
    • OPED
    IO Tribune
    Home » Capricor Faces New Challenge as FDA Schedules DMD Cardio Therapy Review
    Science

    Capricor Faces New Challenge as FDA Schedules DMD Cardio Therapy Review

    Lina Johnson MercilliBy Lina Johnson MercilliJune 28, 2026No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Top Highlights

    1. Capricor was surprised by the FDA’s decision to hold an advisory committee meeting before its August deadline.
    2. The company believes its data is clear, with no issues raised by the FDA so far.
    3. Recent regulatory trends show the FDA is becoming more open to second chances for rare disease drugs.
    4. CEO Linda Marbán remains confident in deramiocel’s approval prospects, citing strong clinical results.

    Unexpected Review Process for DMD Therapy

    The FDA has scheduled an advisory committee meeting for Capricor’s Duchenne muscular dystrophy (DMD) treatment, deramiocel. This surprised the company, which believed all data was clear and positive. Usually, such meetings happen after concerns are raised. However, the FDA’s move suggests they may want to review the data more thoroughly. This unexpected step could delay the therapy’s approval but also shows the agency’s careful approach with new treatments.

    What This Means for Patients and Innovation

    For patients with DMD, this review could be a mixed bag. On one hand, a detailed review ensures safety and effectiveness, which may lead to better long-term outcomes. On the other hand, delays mean families may have to wait longer for promising therapies. Scientific progress is still moving forward, with Capricor’s recent success in clinical trials. Overall, this process might slow approval, but it aims to protect those who need new options most.

    Broader Impact on Drug Development and Regulation

    The FDA’s decision reflects a possible shift in how it handles rare disease treatments. After some high-profile rejections and changes in leadership, the agency seems to be returning to a more cautious but consistent approach. Recently, companies developing therapies for cancer and genetic disorders received approvals after meeting strict standards. While some believe this cautiousness might slow innovation, overall, it could improve safety and trust in new medicines. This careful review could benefit both the biotech industry and patients waiting for life-changing treatments.

    Expand Your Tech Knowledge

    Dive deeper into the world of Space and its vast mysteries.

    Access comprehensive resources on space and science by visiting NASA.

    Sci-BioV1

    Asia Biotech health Innovation Medical medicine Tech VT1
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleQ2 2026: Darkest Quarter for Crypto Hacks
    Next Article China Worries Over Privacy Amid Rise of AI Smart Glasses
    Avatar photo
    Lina Johnson Mercilli
    • Website

    Lina Johnson Marcelli is the editor for IO Tribune, bringing over two decades of experience in journalism to her role. With a BA in Journalism, she is passionate about delivering impactful stories that resonate with readers. Known for her keen editorial vision and leadership, Lina is dedicated to fostering innovative storytelling across the publication. Outside of work, she enjoys exploring new media trends and mentoring aspiring journalists.

    Related Posts

    Gadgets

    Once I tried a Google TV projector, I’m sold!

    June 29, 2026
    AI

    Kickstart Your Data Engineering Journey: Make Pipelines Testable

    June 29, 2026
    Science

    Strawberry Moon 2026: Last Micromoon of the Year Rises

    June 29, 2026
    Add A Comment

    Comments are closed.

    Must Read

    Once I tried a Google TV projector, I’m sold!

    June 29, 2026

    Kickstart Your Data Engineering Journey: Make Pipelines Testable

    June 29, 2026

    Strawberry Moon 2026: Last Micromoon of the Year Rises

    June 29, 2026

    California’s New Law Puts a Muzzle on Loud Streaming Ads Starting July 1

    June 28, 2026

    China Worries Over Privacy Amid Rise of AI Smart Glasses

    June 28, 2026
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    Most Popular

    Apple Watch Blood Oxygen Tracking Sparks New Legal Battle

    August 21, 2025

    Unlock Big Savings on Top Tech: Blink, Anker, Roku & Fire TV!

    October 8, 2025

    Codex Unleashed: A Bold Challenge to Claude Code

    April 16, 2026
    Our Picks

    Whale Frenzy: Ethereum Poised to Soar Past $5,000!

    August 25, 2025

    Concrete Innovation: MIT Taps into AI to Spice Up Recipe for Success!

    June 2, 2025

    Bits Recap Jan 9: Pi Network Updates, Ripple Price Targets & More!

    January 9, 2026
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    • About Us
    • Contact us
    Copyright © 2025 Iotribune.comAll Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.